Related Experiment Video
Updated: Sep 10, 2026
Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
Published on: August 2, 2024
Short-Term Mechanical Circulatory Support Before Heart Transplantation and Early Outcomes: Insights From the
Mercedes Rivas-Lasarte1, Eduard Rodenas-Alesina2, Yasbanoo Moayedi3
1Cardiology Department, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain; Puerta de Hierro-Segovia de Arana Biomedical Research Institute; CIBERCV.
Background:
Heart transplantation (HT) remains the gold-standard therapy for selected patients with advanced heart failure. Increasing recipient complexity and donor organ scarcity have led to the increased use of short-term mechanical circulatory support (ST-MCS) as a bridge to HT. The prognostic impact of ST-MCS on primary graft dysfunction (PGD) and other early outcomes remains limited.
Methods:
We analyzed data from the Primary Graft Dysfunction Consortium, a retrospective registry including 3800 adult HTs at 14 centers in the United States, Canada, and Europe between 2010 and 2020. Primary outcomes were severe PGD (according to International Society for Heart and Lung Transplantation criteria) and 1-year mortality. Multivariable logistic regression and Cox models were used, with multiple imputation for missingness.
Results:
Overall, 669 patients (17.6%) received pre-HT ST-MCS. Among them, 16.9% were supported with extracorporeal membrane oxygenation (ECMO), 60.4% with an intra-aortic balloon pump, 9.1% with a percutaneous left ventricular assist device, 9.1% with surgical ventricular assist devices, and 4.5% with other devices. ST-MCS use increased over time and varied by region, with the intra-aortic balloon pump predominating in the United States and ECMO more frequently used in Canada and Europe. Overall, ST-MCS was not associated with severe PGD after adjustment; however, ECMO was independently associated with greater PGD risk (adjusted odds ratio 3.28, 95% confidence interval 1.90-5.66). One-year mortality was 11.0% and did not differ significantly according to ST-MCS use after multivariable adjustment.
Conclusions:
In this large contemporary multinational cohort, pretransplant ST-MCS use has increased, with geographic heterogeneity observed. Although ECMO is associated with a greater risk of severe PGD, ST-MCS does not independently increase 1-year mortality after HT, supporting its use as a bridge in high-risk patients.
